Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101805 | 0.88 | SMN1; SMN2 (0.52) | SMN1; SMN2LRRK2NPC1RAB9AGRM4 | |
| SCHEMBL7913781 | 0.86 | ALDH1A1 (0.52) | SMN1; SMN2LRRK2NPC1RAB9AGRM4 | |
| SCHEMBL7910114 | 0.86 | LRRK2 (0.53) | SMN1; SMN2LRRK2NPC1RAB9AKMT2A | |
| SCHEMBL7906317 | 0.85 | KMT2A (0.53) | SMN1; SMN2NPC1RAB9ATSHRKMT2A | |
| SCHEMBL7906315 | 0.84 | NPC1 (0.56) | SMN1; SMN2LRRK2NPC1RAB9AGRM4 | |
| SCHEMBL7906320 | 0.83 | GRM4 (0.56) | SMN1; SMN2NPC1RAB9AGRM4HPGD | |
| SCHEMBL7909378 | 0.83 | LRRK2 (0.52) | SMN1; SMN2LRRK2NPC1RAB9AGRM4 | |
| SCHEMBL7913043 | 0.82 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9AGBA1TSHR | |
| SCHEMBL7900427 | 0.82 | KMT2A (0.54) | SMN1; SMN2LRRK2NPC1RAB9ATSHR | |
| SCHEMBL7899805 | 0.82 | LRRK2 (0.54) | SMN1; SMN2LRRK2NPC1RAB9AGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010100050-A1 | PYRIDINE-2-YL-CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227887-A1 | PYRIDINE-2-YL CARBOXYLIC ACID AMIDES | GRM2, GRM1, GRM3 | SMN1; SMN2 2966/4885LRRK2 1918/4885NPC1 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.